NCT01910545已完成1 期
PhaseI, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Number of patients with adverse events and/or dose-limiting toxicities as a measure of safety and tolerability of OTS167 IV infusion.
研究概览
简要总结
The purpose of this study is to test the safety and tolerability of an investigational drug called OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this first-in-human study OTS167 will be administered to patients with solid tumors which have not responded to treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, >= 18 years of age at the time of obtaining informed consent.
- •Patients with a documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic.
- •Patients with a malignancy that is either refractory to standard therapy or for which no standard therapy is available.
- •Patients with a malignancy that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor.
- •Patients with measurable or non-measurable disease according to the response evaluation criteria in solid tumors (RECIST , v1.1)
- •Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or
- •Patients, both male and female, who are either not of childbearing potential or who agree to use a medically effective method of contraception during the study and for 3 months after the last dose of study drug.
- •Patients with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.
排除标准
- •Women who are pregnant or lactating. Women of child-bearing potential (WOCBP), and fertile men with a WOCBP-partner not using adequate birth control.
- •Patients with known central nervous system (CNS) or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
- •Patients with any hematologic malignancy. This includes leukemia (any form), lymphoma, and multiple myeloma.
- •Patients with any of the following hematologic abnormalities at baseline:
- •Absolute neutrophil count (ANC) < 1,500 per mm3
- •Platelet count < 100,000 per mm3
- •Patients with any of the following serum chemistry abnormalities at baseline:
- •Total bilirubin >= 1.5 × the ULN for the institution
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 3 × the upper limit normal (ULN) for the institution (>= 5 × if due to hepatic involvement by tumor)
- •Serum albumin < 2.5 g/dL
- •Creatinine >= 1.5 × ULN for the institution (or a calculated creatinine clearance < 60 mL/min/1.73 m2)
- •Patients with a significant cardiovascular disease or condition, including:
- •Congestive heart failure (CHF) currently requiring therapy
- •Need for antiarrhythmic medical therapy for a ventricular arrhythmia
- •Severe conduction disturbance
- •Angina pectoris requiring therapy
- •Corrected QT (QTc) interval > 450 msec (males) or > 470 msec (females)
- •QTc interval <= 300 msec
- •History of congenital long QT syndrome or congenital short QT syndrome
- •Left ventricular ejection fraction < 50%
- •Uncontrolled hypertension (per the Investigator's discretion)
- •Class III or IV cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria.
- •Myocardial infarction (MI) within 6 months prior to first study drug administration
- •Patients with a known or suspected hypersensitivity to any of the components of OTS
- •Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
- •Patients with any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 1 week prior to first study drug administration.
- •Patients with inadequate recovery from acute toxicity associated with any prior antineoplastic therapy.
- •Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first study drug administration.
- •Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug.
- •Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
- •Patients with the inability or with foreseeable incapacity, in the opinion of the Investigator, to comply with the protocol requirements.
研究组 & 干预措施
OTS167IV
Experimental
single arm
干预措施: OTS167IV (Drug)
结局指标
主要结局
Number of patients with adverse events and/or dose-limiting toxicities as a measure of safety and tolerability of OTS167 IV infusion.
时间窗: Up to 30 days after last dose of study drug
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of LY3532226 in Participants With ObesityObesityNCT06557356Eli Lilly and Company132
已完成
1 期
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy VolunteersHerpes Simplex Virus InfectionNCT02346760United BioPharma15
已完成
1 期
First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT04577703Sunshine Lake Pharma Co., Ltd.20
进行中（未招募）
1 期
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasNCT06226571Syndax Pharmaceuticals76
已完成
1 期
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular DegenerationAge-related Macular DegenerationNCT00569140Ophthotech Corporation18